Market revenue in 2023 | USD 41.6 million |
Market revenue in 2030 | USD 92.5 million |
Growth rate | 12.1% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 36.06% in 2023. Horizon Databook has segmented the Kuwait immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
Kuwait is one of the fastest-growing countries due to its increasing exports and growing economy. With major advancements in its healthcare infrastructure, the country is tackling the growing prevalence of neurological diseases. Therefore, the rising neurodegenerative disease burden in the country is a major factor driving the market.
The MOH Kuwait is responsible for the regulation of pharmaceutical and medical device products in the country. For entry into Kuwait, a company must apply for marketing authorization, which has to be submitted to the MOH for evaluation & approval.
Furthermore, IVD products must meet the product & technical class-specific provisions in the Gulf Health Guidelines and should have been registered with competent authorities, such as the EMA and U.S. FDA.
Horizon Databook provides a detailed overview of country-level data and insights on the Kuwait immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Kuwait immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account